Keyword: Takeda

The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.

The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.

Vaccine trust has fallen in the Philippines since Sanofi's Dengvaxia controversy, and now experts are warning about the threat of measles outbreaks.

Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.

With a critical shareholder vote looming, Takeda's CFO says the company will consider selling up to $10 billion in assets to help fund its Shire buy.

A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.

Citing high risks, Kunio Takeda, the drugmaker's leader from 1993 to 2009, said he doesn't support the Shire acquisition.

Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.

The EU approval is conditional on selling off a Shire experimental IBD drug, which Takeda said could attract "a number of potential buyers."

Ahead of an early December shareholder vote on Takeda's Shire buyout, some Takeda investors and insiders are working to gather support against it.